Entera Bio Ltd. (ENTX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Jerusalem, Israel. The current CEO is Miranda J. Toledano.
ENTX has IPO date of 2018-06-28, 18 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $52.68M.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
